A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16(ecto) directed chimeric antigen receptors for recurrent ovarian cancer.
about
Producer T cells: Using genetically engineered T cells as vehicles to generate and deliver therapeutics to tumorsStrategies to genetically engineer T cells for cancer immunotherapy.Emerging immunotherapeutics in adenocarcinomas: A focus on CAR-T cellsDriving CAR T-cells forwardLeveraging immunotherapy for the treatment of gynecologic cancers in the era of precision medicineCAR-T cell therapy in gastrointestinal tumors and hepatic carcinoma: From bench to bedside.Chimeric antigen receptor T cells: a novel therapy for solid tumors.Study of recombinant human interleukin-12 for treatment of complications after radiotherapy for tumor patientsCancer Immunotherapy: Whence and Whither.The basics of CAR T design and challenges in immunotherapy of solid tumors - Ovarian cancer as a model.Adoptive T-Cell Therapy for Solid Tumors.The future of cancer treatment: immunomodulation, CARs and combination immunotherapy.Armored CAR T-cells: utilizing cytokines and pro-inflammatory ligands to enhance CAR T-cell anti-tumour efficacy.Expression of Tim4 in Glioma and its Regulatory Role in LN-18 Glioma Cells.Engineered T cells: the promise and challenges of cancer immunotherapy.Chimeric antigen receptor-modified T cells for the treatment of solid tumors: Defining the challenges and next steps.T-lymphocyte homing: an underappreciated yet critical hurdle for successful cancer immunotherapy.Review: Current clinical applications of chimeric antigen receptor (CAR) modified T cells.Advancing Immune and Cell-Based Therapies Through Imaging.Current approaches to increase CAR T cell potency in solid tumors: targeting the tumor microenvironment.Development of CAR T cells designed to improve antitumor efficacy and safety.The Multi-Purpose Tool of Tumor Immunotherapy: Gene-Engineered T Cells.Clinical development of CAR T cells-challenges and opportunities in translating innovative treatment conceptsCAR-T cell therapy in ovarian cancer: from the bench to the bedside.Clinical trials of CAR-T cells in ChinaPractical considerations for chimeric antigen receptor design and delivery.Interleukin-armed chimeric antigen receptor-modified T cells for cancer immunotherapy.Shotgun Glycomics Identifies Tumor-Associated Glycan Ligands Bound by an Ovarian Carcinoma-Specific Monoclonal Antibody.Chimeric Antigen Receptor T Cell Therapy: Challenges to Bench-to-Bedside Efficacy.Chimeric Antigen Receptor (CAR) T-Cell Therapy for Thoracic Malignancies.Chimeric antigen receptor T cell (CAR-T) immunotherapy for solid tumors: lessons learned and strategies for moving forward.Preclinical Assessment of CAR T-Cell Therapy Targeting the Tumor Antigen 5T4 in Ovarian Cancer.CAR-T cells: the long and winding road to solid tumors.Overcoming barriers of car T-cell therapy in patients with mesothelin-expressing cancers.IL-36α suppresses proliferation of ovarian cancer cells.Perspectives on Chimeric Antigen Receptor T-Cell Immunotherapy for Solid Tumors.Advances on chimeric antigen receptor-modified T-cell therapy for oncotherapy.Immunotherapy with CAR-Modified T Cells: Toxicities and Overcoming Strategies.Tumor angiogenesis and anti-angiogenic gene therapy for cancer.A Phase 1 trial of autologous monocytes stimulated ex vivo with Sylatron (Peginterferon alfa-2b) and Actimmune (Interferon gamma-1b) for intra-peritoneal administration in recurrent ovarian cancer
P2860
Q26741260-1A2AADE2-02B5-4408-8519-D8AACADAA6BFQ33655849-233D216B-C635-4614-A889-F0A42DE22BF2Q33833475-A2E3825F-F428-4898-8C4F-5235E05F997BQ34046505-355B8DD9-4E65-4E10-AA9B-B308E7E56670Q37224420-6D3FEB6E-1614-4110-A436-C7FBB9098335Q37559401-80EAB4C6-7568-471C-9A3E-A9591C1182A0Q37728639-2399A84D-568A-4C5B-BC95-D924D4269A68Q37743061-BDF7CE8D-79C5-474F-BC8A-1BF0E161DE01Q38737924-CD5F2DEF-C510-41A4-A128-05C2781D68C8Q38748836-D4BA0999-5E0A-41B2-A5B6-3A1FB5182EA9Q38754498-A23715D1-89F6-4F41-AEC4-3D24C4BDBCD5Q38775177-E6B1DC94-332F-42CE-B008-6703026F814EQ38779032-8F90A1BB-2257-4695-8F1F-2F318E9C6C09Q38805940-B0895C66-2DF7-4AD1-B52B-C6D5DE37B95AQ38828829-93F65AFD-86C0-4ED9-A954-B30B051DE11BQ38845812-0840552A-4435-4BC4-8288-5BE0EDC1A151Q38873974-39B0850D-EBE5-4402-BD8A-5BBD6BCE82E2Q38945853-0164911F-0655-4834-9A3C-AFCFB22D5C90Q39167485-E1E78CD5-B580-4BE3-9619-5CEC20E9974EQ39194733-C2F6167D-E42E-4664-8242-23D84BB40432Q39200527-4AB1D126-DE90-46E7-AE14-B4CEEC7F8A4AQ40095245-7BA9D7C8-7C3B-4B3B-9F8A-A5DD9AC49273Q41600980-9A355E3A-4C3B-4ADE-811D-05AB7F5D69A7Q42362802-082FCE2A-A176-42D3-B6C3-3FF8C4015D80Q42654456-6F102AC7-D008-497D-840F-08E4030F3C44Q45868559-5BA5E29D-BBF9-4F98-98E4-8D2AE5E868D9Q45870945-81D5F436-BACB-4D7D-8967-5178FB651E79Q47125093-556A860B-1545-445C-AE2C-2CA526702525Q47193084-3559E4C2-DF57-4E36-B285-F7632E60E081Q47377609-19632A2B-8C0E-43F7-B99A-197EACE53068Q49280922-CF040559-BA99-4DB4-BC6D-BA334C559812Q49843670-20198013-3946-48D7-94D2-2632057EE9A8Q49959264-E90884C1-3A78-411D-81D9-8B54A078F2F9Q50027827-ABCE720A-C810-4851-9D57-8B582E42BF67Q50941305-BC176C24-7EA5-485B-8344-646B0EE4713CQ54965277-020525B7-FFB0-43D7-AC82-789255243A31Q54979818-373C75A0-3247-4623-B510-0C466584515FQ55216327-DF819CCE-9C94-4603-985C-14602DA75CFFQ55385227-941617D1-D320-4838-B9A5-51B1D2BE5117Q56517336-7199B87D-7804-45EA-9C2C-B3FB64D96EFD
P2860
A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16(ecto) directed chimeric antigen receptors for recurrent ovarian cancer.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
A phase I clinical trial of ad ...... for recurrent ovarian cancer.
@ast
A phase I clinical trial of ad ...... for recurrent ovarian cancer.
@en
type
label
A phase I clinical trial of ad ...... for recurrent ovarian cancer.
@ast
A phase I clinical trial of ad ...... for recurrent ovarian cancer.
@en
prefLabel
A phase I clinical trial of ad ...... for recurrent ovarian cancer.
@ast
A phase I clinical trial of ad ...... for recurrent ovarian cancer.
@en
P2093
P2860
P1476
A phase I clinical trial of ad ...... for recurrent ovarian cancer.
@en
P2093
David R Spriggs
Mythili Koneru
Renier J Brentjens
Roisin O'Cearbhaill
Swati Pendharkar
P2860
P2888
P356
10.1186/S12967-015-0460-X
P577
2015-03-28T00:00:00Z
P5875
P6179
1052687172